Literature DB >> 1771965

Perspective on the development of vaccines against Lyme disease.

R Edelman1.   

Abstract

Lyme disease, the multisystem illness caused by the tick-borne spirochaete, Borrelia burgdorferi, has emerged as a threat to public health worldwide. It is a particularly vexing problem in the United States where it is growing in range and intensity. In fact, in some hyperendemic regions of New York and New England, Lyme disease is now such a threat that it interferes with all sorts of outdoor activities, and has even led to depreciation of real estate values. Family dogs in these areas seem to have been particularly hard hit by a near epidemic of lameness caused by Lyme arthritis. Persons at high risk for infection, such as outdoor workers, campers and hikers, suburbanites with lawns to cut, and pregnant women exposed to potentially infected Ixodes ticks, are clamouring for some means of protection beyond simple behaviour modification and tick avoidance which are known not always to work. Hence, the interest in human and veterinary vaccines against Lyme disease is growing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1771965     DOI: 10.1016/0264-410x(91)90236-y

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Lyme disease vaccine.

Authors:  G P Wormser
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

Review 2.  Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.

Authors:  A Sadziene; A G Barbour
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

3.  Recombinant outer-surface protein A (des-Cys1-OspA) from the Lyme disease spirochete Borrelia burgdorferi: high production levels in Saccharomyces cerevisiae yeast cultures.

Authors:  O Mendoza-Vega; E Keppi; B Bouchon; M Nguyen; T Achstetter
Journal:  Appl Microbiol Biotechnol       Date:  1996-01       Impact factor: 4.813

4.  Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.

Authors:  W S Probert; R B LeFebvre
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Identification and characterization of a surface-exposed, 66-kilodalton protein from Borrelia burgdorferi.

Authors:  W S Probert; K M Allsup; R B LeFebvre
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.